Compugen reported $1.82M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
aTyr Pharma USD 1.31M 2.04M Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Clal Biotechnology ILS 16.49M 2.64M Jun/2022
Compugen USD 1.82M 1.71M Mar/2026
Minerva Neurosciences 386K 31K Jun/2024
RedHill Biopharma USD 702K 0 Jun/2024
TherapeuticsMD USD -11.99M 12.34M Dec/2022